OncoMatch/Clinical Trials/NCT06496971
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
Is NCT06496971 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Bevacizumab and Microbubble for glioblastoma multiforme.
Treatment: Bevacizumab · Microbubble · Low-Intensity Focused Ultrasound — This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: radiation therapy
following prior radiotherapy
Must have received: chemotherapy (temozolomide)
following prior...temozolomide chemotherapy
Cannot have received: anti-angiogenic therapy (bevacizumab)
previous treatment with anti-angiogenic therapy, including Bevacizumab, or other VEGF inhibitors or VEGF-receptor signaling inhibitors
Cannot have received: VEGF inhibitor
previous treatment with anti-angiogenic therapy, including Bevacizumab, or other VEGF inhibitors or VEGF-receptor signaling inhibitors
Cannot have received: VEGFR inhibitor
previous treatment with anti-angiogenic therapy, including Bevacizumab, or other VEGF inhibitors or VEGF-receptor signaling inhibitors
Cannot have received: nitrosourea (Carmustine wafers)
previously received Carmustine wafers implantation during re-operation
Cannot have received: tumor treating fields
previously received or are currently undergoing tumor treating fields (TTF) treatment
Lab requirements
Blood counts
Hemoglobin ≥ 10 g/dL; Platelets ≥ 100,000/mm3; Neutrophils ≥ 1,500/mm3
Kidney function
Serum creatinine ≤ 1.5 × ULN; Urine protein creatinine ratio (UPCR) < 1 or urine dipstick for proteinuria ≤ 2+
Liver function
ALT < 3 × ULN; AST < 3 × ULN; Total bilirubin < 2 × ULN
Adequate hematopoietic, renal, hepatic, and coagulation function, defined as: Hemoglobin ≥ 10 g/dL; Platelets ≥ 100,000/mm3; Neutrophils ≥ 1,500/mm3; Serum creatinine ≤ 1.5 × ULN; Urine protein creatinine ratio (UPCR) < 1 or urine dipstick for proteinuria ≤ 2+; Alanine aminotransferase (ALT) < 3 × ULN; Aspartate aminotransferase (AST) < 3 × ULN; Total bilirubin (TBL) < 2 × ULN; Prothrombin time ≤ 1.5 x ULN; International Normalized Ratio (INR) < 1.5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify